GLOBUS MEDICAL INC - A (GMED) Stock Fundamental Analysis
NYSE:GMED - New York Stock Exchange, Inc. - US3795772082 - Common Stock - Currency: USD
GMED gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. GMED scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMED is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make GMED a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
GMED had positive earnings in the past year.
GMED had a positive operating cash flow in the past year.
In the past 5 years GMED has always been profitable.
Each year in the past 5 years GMED had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.94%, GMED belongs to the top of the industry, outperforming 81.38% of the companies in the same industry.
GMED has a Return On Equity of 4.54%. This is in the better half of the industry: GMED outperforms 78.19% of its industry peers.
GMED has a better Return On Invested Capital (8.24%) than 87.23% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GMED is in line with the industry average of 7.89%.
The last Return On Invested Capital (8.24%) for GMED is above the 3 year average (7.50%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.94% | ||
| ROE | 4.54% | ||
| ROIC | 8.24% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)7.5%
ROIC(5y)7.39%
1.3 Margins
Looking at the Profit Margin, with a value of 7.39%, GMED belongs to the top of the industry, outperforming 80.32% of the companies in the same industry.
GMED's Profit Margin has declined in the last couple of years.
GMED has a better Operating Margin (17.79%) than 89.36% of its industry peers.
In the last couple of years the Operating Margin of GMED has declined.
Looking at the Gross Margin, with a value of 66.86%, GMED is in the better half of the industry, outperforming 71.28% of the companies in the same industry.
GMED's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.79% | ||
| PM (TTM) | 7.39% | ||
| GM | 66.86% |
OM growth 3Y-4.88%
OM growth 5Y-4.91%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-3.49%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
GMED has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, GMED has more shares outstanding
GMED has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GMED is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.42 indicates that GMED is not in any danger for bankruptcy at the moment.
GMED's Altman-Z score of 9.42 is amongst the best of the industry. GMED outperforms 88.83% of its industry peers.
The Debt to FCF ratio of GMED is 0.00, which is an excellent value as it means it would take GMED, only 0.00 years of fcf income to pay off all of its debts.
GMED has a better Debt to FCF ratio (0.00) than 95.74% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GMED is not too dependend on debt financing.
GMED's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. GMED outperforms 71.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 9.42 |
ROIC/WACC0.93
WACC8.86%
2.3 Liquidity
GMED has a Current Ratio of 4.45. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
GMED's Current ratio of 4.45 is fine compared to the rest of the industry. GMED outperforms 68.62% of its industry peers.
GMED has a Quick Ratio of 2.72. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
GMED has a Quick ratio of 2.72. This is in the better half of the industry: GMED outperforms 61.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.45 | ||
| Quick Ratio | 2.72 |
3. Growth
3.1 Past
GMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.02%, which is quite impressive.
Measured over the past years, GMED shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.19% on average per year.
Looking at the last year, GMED shows a very strong growth in Revenue. The Revenue has grown by 32.26%.
Measured over the past years, GMED shows a very strong growth in Revenue. The Revenue has been growing by 26.25% on average per year.
EPS 1Y (TTM)23.02%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%-5.56%
Revenue 1Y (TTM)32.26%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%-1.41%
3.2 Future
GMED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.10% yearly.
GMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.25% yearly.
EPS Next Y6.18%
EPS Next 2Y9.85%
EPS Next 3Y10.77%
EPS Next 5Y12.1%
Revenue Next Year13.86%
Revenue Next 2Y11.41%
Revenue Next 3Y9.87%
Revenue Next 5Y7.25%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.53, GMED is valued on the expensive side.
Based on the Price/Earnings ratio, GMED is valued cheaply inside the industry as 80.32% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.55, GMED is valued a bit cheaper.
With a Price/Forward Earnings ratio of 15.98, GMED is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 80.85% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of GMED to the average of the S&P500 Index (22.40), we can say GMED is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.53 | ||
| Fwd PE | 15.98 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 89.36% of the companies listed in the same industry.
GMED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GMED is cheaper than 90.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.83 | ||
| EV/EBITDA | 10.92 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
GMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.16
PEG (5Y)1.48
EPS Next 2Y9.85%
EPS Next 3Y10.77%
5. Dividend
5.1 Amount
GMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:GMED (6/12/2025, 2:47:58 PM)
60.53
-0.27 (-0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners98.44%
Inst Owner Change3.15%
Ins Owners0.76%
Ins Owner Change-0.98%
Market Cap8.19B
Analysts76.19
Price Target87.63 (44.77%)
Short Float %4.02%
Short Ratio2.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.04%
Min EPS beat(2)-10.39%
Max EPS beat(2)10.48%
EPS beat(4)3
Avg EPS beat(4)8.53%
Min EPS beat(4)-10.39%
Max EPS beat(4)25.45%
EPS beat(8)5
Avg EPS beat(8)7.1%
EPS beat(12)8
Avg EPS beat(12)4.94%
EPS beat(16)11
Avg EPS beat(16)5.07%
Revenue beat(2)1
Avg Revenue beat(2)-3.08%
Min Revenue beat(2)-6.31%
Max Revenue beat(2)0.16%
Revenue beat(4)3
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)1.57%
Revenue beat(8)5
Avg Revenue beat(8)-1.66%
Revenue beat(12)6
Avg Revenue beat(12)-0.98%
Revenue beat(16)8
Avg Revenue beat(16)-0.43%
PT rev (1m)-11.85%
PT rev (3m)-12.2%
EPS NQ rev (1m)-9.37%
EPS NQ rev (3m)-9.79%
EPS NY rev (1m)-4.98%
EPS NY rev (3m)-4.84%
Revenue NQ rev (1m)10.18%
Revenue NQ rev (3m)10.12%
Revenue NY rev (1m)1.82%
Revenue NY rev (3m)6.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.53 | ||
| Fwd PE | 15.98 | ||
| P/S | 3.26 | ||
| P/FCF | 15.83 | ||
| P/OCF | 12.69 | ||
| P/B | 2 | ||
| P/tB | 4.35 | ||
| EV/EBITDA | 10.92 |
EPS(TTM)3.1
EY5.12%
EPS(NY)3.79
Fwd EY6.26%
FCF(TTM)3.82
FCFY6.32%
OCF(TTM)4.77
OCFY7.88%
SpS18.55
BVpS30.2
TBVpS13.91
PEG (NY)3.16
PEG (5Y)1.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.94% | ||
| ROE | 4.54% | ||
| ROCE | 10.32% | ||
| ROIC | 8.24% | ||
| ROICexc | 9.22% | ||
| ROICexgc | 21.46% | ||
| OM | 17.79% | ||
| PM (TTM) | 7.39% | ||
| GM | 66.86% | ||
| FCFM | 20.61% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)7.5%
ROIC(5y)7.39%
ROICexc(3y)9.36%
ROICexc(5y)9.51%
ROICexgc(3y)18.38%
ROICexgc(5y)15.86%
ROCE(3y)9.4%
ROCE(5y)9.26%
ROICexcg growth 3Y25.82%
ROICexcg growth 5Y11.96%
ROICexc growth 3Y-3.93%
ROICexc growth 5Y-4.62%
OM growth 3Y-4.88%
OM growth 5Y-4.91%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-3.49%
GM growth 5Y-2.63%
F-Score9
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 48.32% | ||
| Cap/Sales | 5.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.74% | ||
| Profit Quality | 278.93% | ||
| Current Ratio | 4.45 | ||
| Quick Ratio | 2.72 | ||
| Altman-Z | 9.42 |
F-Score9
WACC8.86%
ROIC/WACC0.93
Cap/Depr(3y)69.29%
Cap/Depr(5y)78.11%
Cap/Sales(3y)5.6%
Cap/Sales(5y)6.16%
Profit Quality(3y)194.29%
Profit Quality(5y)172.4%
High Growth Momentum
Growth
EPS 1Y (TTM)23.02%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%-5.56%
EPS Next Y6.18%
EPS Next 2Y9.85%
EPS Next 3Y10.77%
EPS Next 5Y12.1%
Revenue 1Y (TTM)32.26%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%-1.41%
Revenue Next Year13.86%
Revenue Next 2Y11.41%
Revenue Next 3Y9.87%
Revenue Next 5Y7.25%
EBIT growth 1Y157.29%
EBIT growth 3Y31.28%
EBIT growth 5Y20.06%
EBIT Next Year59.56%
EBIT Next 3Y26.02%
EBIT Next 5Y19.9%
FCF growth 1Y342%
FCF growth 3Y22.69%
FCF growth 5Y31.98%
OCF growth 1Y245.03%
OCF growth 3Y23.51%
OCF growth 5Y24.8%